- Home
- CISS vs INM Comparison
CISS vs INM Comparison
Compare CISS & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CISS
- INM
- Stock Information
- Founded
- CISS 2022
- INM 1981
- Country
- CISS Greece
- INM Canada
- Employees
- CISS N/A
- INM N/A
- Industry
- CISS Marine Transportation
- INM Biotechnology: Pharmaceutical Preparations
- Sector
- CISS Consumer Discretionary
- INM Health Care
- Exchange
- CISS Nasdaq
- INM Nasdaq
- Market Cap
- CISS 2.8M
- INM 3.2M
- IPO Year
- CISS N/A
- INM N/A
- Fundamental
- Price
- CISS $3.35
- INM $2.75
- Analyst Decision
- CISS
- INM
- Analyst Count
- CISS 0
- INM 0
- Target Price
- CISS N/A
- INM N/A
- AVG Volume (30 Days)
- CISS 124.0K
- INM 5.7M
- Earning Date
- CISS 08-21-2025
- INM 05-12-2025
- Dividend Yield
- CISS N/A
- INM N/A
- EPS Growth
- CISS N/A
- INM N/A
- EPS
- CISS N/A
- INM N/A
- Revenue
- CISS $38,174,754.00
- INM $4,920,990.00
- Revenue This Year
- CISS N/A
- INM N/A
- Revenue Next Year
- CISS N/A
- INM N/A
- P/E Ratio
- CISS N/A
- INM N/A
- Revenue Growth
- CISS N/A
- INM N/A
- 52 Week Low
- CISS $2.85
- INM $1.72
- 52 Week High
- CISS $23.25
- INM $15.70
- Technical
- Relative Strength Index (RSI)
- CISS 44.02
- INM 46.31
- Support Level
- CISS $3.26
- INM $2.66
- Resistance Level
- CISS $3.49
- INM $2.97
- Average True Range (ATR)
- CISS 0.23
- INM 0.37
- MACD
- CISS -0.00
- INM -0.05
- Stochastic Oscillator
- CISS 28.72
- INM 15.12
About CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of our fleet is approximately 64,000 dwt.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.